Socio-demographic determinants of the knowledge of Monkeypox Virus among the general public: a cross-sectional study in a Tertiary Care Center in Nepal.

Publication date: Mar 06, 2024

Monkeypox virus (MPXV) is the causative agent of monkeypox’s zoonotic infection and was declared a global emergency by the World Health Organization (WHO). Studies from different countries have shown insufficient knowledge among the general public on MPXV. This study aimed to assess the knowledge of the general public of Nepal on MPXV. Three hundred people were interviewed in person in October 2022, and 282 complete responses were recorded. The questionnaire related to the knowledge of MPXV was derived from a previous study conducted among the general population of Saudi Arabia. Twenty-two questions were included that assessed the knowledge and attitude of Nepalese toward monkeypox. Statistical comparison between high and low knowledge was performed using Pearson’s Chi-square test. Logistic regression models were deployed to establish the relationship between participants’ knowledge and socio-demographic characteristics. Among the total respondents, 53. 8% demonstrated high knowledge of monkeypox. People aged 18-25 years, unmarried people, and those living in urban areas had significantly higher levels of knowledge. Most respondents believed that MPXV is not a conspiracy or bioterrorism (63. 1%) and agreed that it is likely to affect people’s social and economic life as COVID-19 did (67. 0%). The history of COVID-19 vaccination (aOR: 2. 980; 95%CI: 1. 227, 7. 236) and the younger age (aOR: 2. 975; 95%CI: 1. 097, 8. 069) were found to be significant determinants of the knowledge of the participants on monkeypox. We observed that most Nepalese populations had a high knowledge of monkeypox and that social media was the most valuable source of information.

Open Access PDF

Concepts Keywords
Bioterrorism Knowledge
Monkeypox Monkey pox
Nepalese MPXV
Vaccination Nepal
Population
Virus

Semantics

Type Source Name
disease VO Monkeypox virus
disease MESH monkeypox
disease MESH zoonotic infection
disease MESH emergency
disease VO organization
disease VO population
disease MESH COVID-19
disease IDO history
disease VO vaccination
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH smallpox
drug DRUGBANK Nonoxynol-9
disease IDO colony
disease IDO facility
disease MESH infection
disease VO USA
disease MESH death
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Coenzyme M
disease MESH pneumonia
disease MESH proctitis
disease MESH sepsis
disease MESH superinfections
disease VO time
drug DRUGBANK Hexadecanal
disease VO Ply
disease IDO site
drug DRUGBANK BIA
disease VO age
disease MESH marital status
disease MESH chronic conditions
disease VO monthly
drug DRUGBANK Aspartame
disease VO frequency
disease VO vaccinated
disease MESH viral infection
disease MESH dengue
disease IDO infectious disease
disease MESH Chickenpox
disease VO vaccine
drug DRUGBANK Varicella Zoster Vaccine (Live/Attenuated)
disease VO smallpox vaccine
disease VO Viruses
drug DRUGBANK Indoleacetic acid
disease IDO country
drug DRUGBANK Trestolone

Original Article

(Visited 1 times, 1 visits today)